Updates from Syncona and our portfolio companies
- Experienced clinical leader with extensive experience in guiding rare disease therapies to registration - London, 23 March, 2020 – Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced the appointment of Julie Krop M.D., as Chief Medical Officer (CMO) effective 1 April, 2020.
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces that the European Commission (EC) has granted orphan drug designation for FLT190 for the treatment of Fabry Disease, based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).
Gyroscope Therapeutics, a company developing gene therapies and surgical delivery systems for retinal diseases, announces the strengthening of its leadership team with the hiring of Dr. Nadia Waheed from Tufts University School of Medicine in Boston as Chief Medical Officer (CMO) and the promotion of Dr. Jane Hughes, formerly VP Translational Research, to Chief Scientific Officer (CSO).
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces it will present data on its gene therapy programmes for Fabry Disease and Gaucher Disease at the 16th annual WORLDSymposium™ in Orlando, Florida, 10–13 February 2020. Freeline data has been selected for two oral presentations and associated posters at the conference.
- A biopharma executive with significant experience in commercialisation of treatments for rare diseases joining Freeline after senior roles at leading global rare disease companies including Alnylam and Shire -